Abstract

Background: Oral squamous cell carcinoma (OSCC) is one of the most common malignancies recognized nowadays. Its early detection is the better alternative to provide a good quality of life for the patients. During the last years, several studies have identified potential biomarkers of OSCC progression and prognosis. The phosphodiesterases (PDEs) are responsible for the hydrolysis of the second messengers with a fundamental role in the transduction of the intracellular signals. Variations in PDE activity have been correlated to different pathological mechanisms, such as cellular differentiation, apoptosis, and tumor invasivity. PDEs are also known to play a role in tumor growth by influencing angiogenesis. Aim: To estimate and compare serum PDE levels in healthy controls and biopsy-proven oral cancer patients before definitive therapy. Materials and Methods: Institutional Ethics Committee gave us the permission to conduct this study. After obtaining consent from biopsy-proven oral cancer patients (n = 39) (before onset of any definitive treatment) and age- and sex-matched healthy controls (n = 20), 2 ml of blood was collected in plain vacutainers. After clot formation, samples were centrifuged and serum was collected for estimation of PDE. Statistical Analysis: Kruskal-Wallis test; Mann-Whitney Test Results and Discussion: Pretreatment PDE levels were significantly elevated in oral cancer patients (P<0.0001) as compared with the controls and also there was a significant increase in PDE levels (P<0.001) with advancing stage in oral cancer patients. This may implicate a role for serum PDE in pathophysiology of oral cancer.

Original languageEnglish
Pages (from-to)180-182
Number of pages3
JournalJournal of Cancer Research and Therapeutics
Volume7
Issue number2
DOIs
Publication statusPublished - 04-2011

Fingerprint

Mouth Neoplasms
Phosphoric Diester Hydrolases
Serum
Squamous Cell Carcinoma
Biopsy
Neoplasms
Ethics Committees
Second Messenger Systems
Signal Transduction
Hydrolysis
Biomarkers
Quality of Life
Apoptosis
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{4071430d45fc4ff88d4b5b166003f4a0,
title = "Serum phosphodiesterase levels in oral cancer",
abstract = "Background: Oral squamous cell carcinoma (OSCC) is one of the most common malignancies recognized nowadays. Its early detection is the better alternative to provide a good quality of life for the patients. During the last years, several studies have identified potential biomarkers of OSCC progression and prognosis. The phosphodiesterases (PDEs) are responsible for the hydrolysis of the second messengers with a fundamental role in the transduction of the intracellular signals. Variations in PDE activity have been correlated to different pathological mechanisms, such as cellular differentiation, apoptosis, and tumor invasivity. PDEs are also known to play a role in tumor growth by influencing angiogenesis. Aim: To estimate and compare serum PDE levels in healthy controls and biopsy-proven oral cancer patients before definitive therapy. Materials and Methods: Institutional Ethics Committee gave us the permission to conduct this study. After obtaining consent from biopsy-proven oral cancer patients (n = 39) (before onset of any definitive treatment) and age- and sex-matched healthy controls (n = 20), 2 ml of blood was collected in plain vacutainers. After clot formation, samples were centrifuged and serum was collected for estimation of PDE. Statistical Analysis: Kruskal-Wallis test; Mann-Whitney Test Results and Discussion: Pretreatment PDE levels were significantly elevated in oral cancer patients (P<0.0001) as compared with the controls and also there was a significant increase in PDE levels (P<0.001) with advancing stage in oral cancer patients. This may implicate a role for serum PDE in pathophysiology of oral cancer.",
author = "K. Prabhu and D. Naik and S. Ray and Vadiraja, {B. M.} and A. Kamath",
year = "2011",
month = "4",
doi = "10.4103/0973-1482.82911",
language = "English",
volume = "7",
pages = "180--182",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Serum phosphodiesterase levels in oral cancer. / Prabhu, K.; Naik, D.; Ray, S.; Vadiraja, B. M.; Kamath, A.

In: Journal of Cancer Research and Therapeutics, Vol. 7, No. 2, 04.2011, p. 180-182.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum phosphodiesterase levels in oral cancer

AU - Prabhu, K.

AU - Naik, D.

AU - Ray, S.

AU - Vadiraja, B. M.

AU - Kamath, A.

PY - 2011/4

Y1 - 2011/4

N2 - Background: Oral squamous cell carcinoma (OSCC) is one of the most common malignancies recognized nowadays. Its early detection is the better alternative to provide a good quality of life for the patients. During the last years, several studies have identified potential biomarkers of OSCC progression and prognosis. The phosphodiesterases (PDEs) are responsible for the hydrolysis of the second messengers with a fundamental role in the transduction of the intracellular signals. Variations in PDE activity have been correlated to different pathological mechanisms, such as cellular differentiation, apoptosis, and tumor invasivity. PDEs are also known to play a role in tumor growth by influencing angiogenesis. Aim: To estimate and compare serum PDE levels in healthy controls and biopsy-proven oral cancer patients before definitive therapy. Materials and Methods: Institutional Ethics Committee gave us the permission to conduct this study. After obtaining consent from biopsy-proven oral cancer patients (n = 39) (before onset of any definitive treatment) and age- and sex-matched healthy controls (n = 20), 2 ml of blood was collected in plain vacutainers. After clot formation, samples were centrifuged and serum was collected for estimation of PDE. Statistical Analysis: Kruskal-Wallis test; Mann-Whitney Test Results and Discussion: Pretreatment PDE levels were significantly elevated in oral cancer patients (P<0.0001) as compared with the controls and also there was a significant increase in PDE levels (P<0.001) with advancing stage in oral cancer patients. This may implicate a role for serum PDE in pathophysiology of oral cancer.

AB - Background: Oral squamous cell carcinoma (OSCC) is one of the most common malignancies recognized nowadays. Its early detection is the better alternative to provide a good quality of life for the patients. During the last years, several studies have identified potential biomarkers of OSCC progression and prognosis. The phosphodiesterases (PDEs) are responsible for the hydrolysis of the second messengers with a fundamental role in the transduction of the intracellular signals. Variations in PDE activity have been correlated to different pathological mechanisms, such as cellular differentiation, apoptosis, and tumor invasivity. PDEs are also known to play a role in tumor growth by influencing angiogenesis. Aim: To estimate and compare serum PDE levels in healthy controls and biopsy-proven oral cancer patients before definitive therapy. Materials and Methods: Institutional Ethics Committee gave us the permission to conduct this study. After obtaining consent from biopsy-proven oral cancer patients (n = 39) (before onset of any definitive treatment) and age- and sex-matched healthy controls (n = 20), 2 ml of blood was collected in plain vacutainers. After clot formation, samples were centrifuged and serum was collected for estimation of PDE. Statistical Analysis: Kruskal-Wallis test; Mann-Whitney Test Results and Discussion: Pretreatment PDE levels were significantly elevated in oral cancer patients (P<0.0001) as compared with the controls and also there was a significant increase in PDE levels (P<0.001) with advancing stage in oral cancer patients. This may implicate a role for serum PDE in pathophysiology of oral cancer.

UR - http://www.scopus.com/inward/record.url?scp=79960763443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960763443&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.82911

DO - 10.4103/0973-1482.82911

M3 - Article

VL - 7

SP - 180

EP - 182

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 2

ER -